

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Emerging approaches to target mitochondrial... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1793/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1793" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Emerging approaches to target mitochondrial apoptosis in cancer cells" />
    
            <meta name="og:title" content="F1000Research Article: Emerging approaches to target mitochondrial apoptosis in cancer cells.">
            <meta name="og:description" content="Read the latest article version by Andrew Gilmore, Louise King, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20683">
            <meta name="article-id" content="18872">
            <meta name="dc.title" content="Emerging approaches to target mitochondrial apoptosis in cancer cells">
            <meta name="dc.description" content="Apoptosis is a highly conserved programme for removing damaged and unwanted cells. Apoptosis in most cells is coordinated on mitochondria by the Bcl-2 family of proteins. The balance between pro- and anti-apoptotic Bcl-2 family proteins sets a threshold for mitochondrial apoptosis, a balance that is altered during cancer progression. Consequently, avoidance of cell death is an established cancer hallmark. Although there is a general perception that tumour cells are more resistant to apoptosis than their normal counterparts, the realities of cell death regulation in cancer are more nuanced. In this review we discuss how a profound understanding of this control has led to new therapeutic approaches, including the new class of BH3-mimetics, which directly target apoptosis as a vulnerability in cancer. We discuss recent findings that highlight the current limitations in our understanding of apoptosis and how these novel therapeutics work.">
            <meta name="dc.subject" content="Apoptosis, BH3-mimetics, cancer">
            <meta name="dc.creator" content="Gilmore, Andrew">
            <meta name="dc.creator" content="King, Louise">
            <meta name="dc.date" content="2019/10/24">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18872.1">
            <meta name="dc.source" content="F1000Research 2019 8:1793">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Apoptosis">
            <meta name="prism.keyword" content="BH3-mimetics">
            <meta name="prism.keyword" content="cancer">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/10/24">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1793">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18872.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1793">
            <meta name="citation_title" content="Emerging approaches to target mitochondrial apoptosis in cancer cells">
            <meta name="citation_abstract" content="Apoptosis is a highly conserved programme for removing damaged and unwanted cells. Apoptosis in most cells is coordinated on mitochondria by the Bcl-2 family of proteins. The balance between pro- and anti-apoptotic Bcl-2 family proteins sets a threshold for mitochondrial apoptosis, a balance that is altered during cancer progression. Consequently, avoidance of cell death is an established cancer hallmark. Although there is a general perception that tumour cells are more resistant to apoptosis than their normal counterparts, the realities of cell death regulation in cancer are more nuanced. In this review we discuss how a profound understanding of this control has led to new therapeutic approaches, including the new class of BH3-mimetics, which directly target apoptosis as a vulnerability in cancer. We discuss recent findings that highlight the current limitations in our understanding of apoptosis and how these novel therapeutics work.">
            <meta name="citation_description" content="Apoptosis is a highly conserved programme for removing damaged and unwanted cells. Apoptosis in most cells is coordinated on mitochondria by the Bcl-2 family of proteins. The balance between pro- and anti-apoptotic Bcl-2 family proteins sets a threshold for mitochondrial apoptosis, a balance that is altered during cancer progression. Consequently, avoidance of cell death is an established cancer hallmark. Although there is a general perception that tumour cells are more resistant to apoptosis than their normal counterparts, the realities of cell death regulation in cancer are more nuanced. In this review we discuss how a profound understanding of this control has led to new therapeutic approaches, including the new class of BH3-mimetics, which directly target apoptosis as a vulnerability in cancer. We discuss recent findings that highlight the current limitations in our understanding of apoptosis and how these novel therapeutics work.">
            <meta name="citation_keywords" content="Apoptosis, BH3-mimetics, cancer">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Andrew Gilmore">
            <meta name="citation_author_institution" content="Wellcome Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK">
            <meta name="citation_author" content="Louise King">
            <meta name="citation_author_institution" content="Wellcome Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK">
            <meta name="citation_publication_date" content="2019/10/24">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1793">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18872.1">
            <meta name="citation_firstpage" content="1793">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1793/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1793.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20683 /> <input type=hidden id=articleId name=articleId value=18872 /> <input type=hidden id=xmlUrl value="/articles/8-1793/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1793-v1.xml"> <input type=hidden id=article_uuid value=5c0427d5-4cff-45c4-863d-eec794ea9ffa /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Emerging approaches to target mitochondrial apoptosis in cancer cells"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18872.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18872.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1793"
  },
  "headline": "Emerging approaches to target mitochondrial apoptosis in cancer cells",
  "datePublished": "2019-10-24T14:17:45",
  "dateModified": "2019-10-24T14:17:45",
  "author": [
    {
      "@type": "Person",
      "name": "Andrew Gilmore"
    },    {
      "@type": "Person",
      "name": "Louise King"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Apoptosis is a highly conserved programme for removing damaged and unwanted cells. Apoptosis in most cells is coordinated on mitochondria by the Bcl-2 family of proteins. The balance between pro- and anti-apoptotic Bcl-2 family proteins sets a threshold for mitochondrial apoptosis, a balance that is altered during cancer progression. Consequently, avoidance of cell death is an established cancer hallmark. Although there is a general perception that tumour cells are more resistant to apoptosis than their normal counterparts, the realities of cell death regulation in cancer are more nuanced. In this review we discuss how a profound understanding of this control has led to new therapeutic approaches, including the new class of BH3-mimetics, which directly target apoptosis as a vulnerability in cancer. We discuss recent findings that highlight the current limitations in our understanding of apoptosis and how these novel therapeutics work."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1793/v1",
            "name": "Emerging approaches to target mitochondrial apoptosis in cancer cells"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Emerging approaches to target mitochondrial apoptosis in cancer cells </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20683 data-id=18872 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18872.1" data-recommended="" data-doi="10.12688/f1000research.18872.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1793/v1/pdf?article_uuid=5c0427d5-4cff-45c4-863d-eec794ea9ffa" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18872-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18872-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18872-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gilmore A and King L. Emerging approaches to target mitochondrial apoptosis in cancer cells [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1793 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18872.1" target=_blank>https://doi.org/10.12688/f1000research.18872.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18872-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18872 id=track-article-signin-18872 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18872?target=/articles/8-1793/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20683 /> <input name=articleId type=hidden value=18872 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Emerging approaches to target mitochondrial apoptosis in cancer cells</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:agilmore@manchester.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Andrew Gilmore</span></a><a href="https://orcid.org/0000-0002-9988-0436" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9988-0436</div>,&nbsp;</span><span class="">Louise King<a href="https://orcid.org/0000-0003-2453-8887" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2453-8887</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:agilmore@manchester.ac.uk" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Andrew Gilmore</span></a><a href="http://orcid.org/0000-0002-9988-0436" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9988-0436</div>,&nbsp;</span><span class="">Louise King<a href="http://orcid.org/0000-0003-2453-8887" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2453-8887</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 24 Oct 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18872.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Wellcome Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK<br/> <p> <div class=margin-bottom> Andrew Gilmore <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Louise King <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=58777-55684></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=58778-55685></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=58779-55686></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Apoptosis is a highly conserved programme for removing damaged and unwanted cells. Apoptosis in most cells is coordinated on mitochondria by the Bcl-2 family of proteins. The balance between pro- and anti-apoptotic Bcl-2 family proteins sets a threshold for mitochondrial apoptosis, a balance that is altered during cancer progression. Consequently, avoidance of cell death is an established cancer hallmark. Although there is a general perception that tumour cells are more resistant to apoptosis than their normal counterparts, the realities of cell death regulation in cancer are more nuanced. In this review we discuss how a profound understanding of this control has led to new therapeutic approaches, including the new class of BH3-mimetics, which directly target apoptosis as a vulnerability in cancer. We discuss recent findings that highlight the current limitations in our understanding of apoptosis and how these novel therapeutics work. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Apoptosis, BH3-mimetics, cancer </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Andrew Gilmore (<a href="mailto:agilmore@manchester.ac.uk">agilmore@manchester.ac.uk</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Andrew Gilmore </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> LK was funded through the Manchester Cancer Research Centre by a Cancer Research UK (CRUK) training award. The Wellcome Centre for Cell-Matrix Research is supported by a core grant from the Wellcome Trust <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Gilmore A and King L. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gilmore A and King L. Emerging approaches to target mitochondrial apoptosis in cancer cells [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1793 (<a href="https://doi.org/10.12688/f1000research.18872.1" target=_blank>https://doi.org/10.12688/f1000research.18872.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 24 Oct 2019, <b>8</b>(F1000 Faculty Rev):1793 (<a href="https://doi.org/10.12688/f1000research.18872.1" target=_blank>https://doi.org/10.12688/f1000research.18872.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 24 Oct 2019, <b>8</b>(F1000 Faculty Rev):1793 (<a href="https://doi.org/10.12688/f1000research.18872.1" target=_blank>https://doi.org/10.12688/f1000research.18872.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d35936e142>Introduction</h2><p class="" id=d35936e145>An important issue in cancer therapy is how to target tumour cell populations whilst minimising impact on healthy surrounding cells. Dose-limiting toxicity is a major problem restricting the treatment to patients, particularly with the types of cytotoxic agents used for more advanced tumours. These types of drugs can be as harmful to many healthy tissues as they are to the tumour cells. Cytotoxic chemotherapy kills cancer cells by inducing apoptosis. Although resistance to apoptosis is an established cancer hallmark, how sensitivity differs between tumours and normal tissues is a more complex and nuanced issue than simply that cancer cells are more resistant to cell death. The increased understanding of apoptosis that has developed over the past decades is now providing new opportunities for targeting vulnerabilities in cancer.</p><p class="" id=d35936e148>The concept of selectively activating cell death in cancer cells has a long history<sup><a href="#ref-1">1</a></sup>. Programmed cell death can occur via a number of mechanisms, including apoptosis and necroptosis, regulated by distinct signalling pathways. A number of these cell death signalling pathways have been exploited with varying success as potential therapeutic targets<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. The disappointing early clinical results with some approaches have been due, in part, to an incomplete understanding of the underlying biology. The successful development of venetoclax highlights how understanding the underlying mechanisms allows rational drug design targeted specifically at apoptotic regulators<sup><a href="#ref-4">4</a></sup>. In this review, we examine the successful exploitation of mitochondrial apoptosis to develop these novel therapeutic approaches and we discuss some of the potential future issues surrounding them.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35936e169>Bcl-2 proteins: setting the apoptotic landscape for cell death</h2><p class="" id=d35936e172><i>BCL-2</i> was initially identified at the site of the t(14;18) chromosomal translocation in patients with B-cell lymphoma<sup><a href="#ref-5">5</a></sup>. The positioning of <i>BCL-2</i> at the translocation junction near the immunoglobulin locus altered its transcriptional regulation but this did not drive proliferation like other oncogenes<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. The realisation that Bcl-2 protein overexpression contributed to oncogenesis by inhibiting programmed cell death kick-started studies leading to the identification of a family of apoptosis regulators<sup><a href="#ref-8">8</a></sup> and established evasion of apoptosis as a central hallmark of cancer<sup><a href="#ref-9">9</a></sup>. Now, nearly 20 members of the Bcl-2 protein family have been confirmed in vertebrates<sup><a href="#ref-10">10</a></sup>, and the multitude of interactions between these proteins is central to how both normal and cancer cells respond to cytotoxic damage (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20683/195e2b77-b16b-4617-b586-34f1ce67bb40_figure1.gif"><img alt="195e2b77-b16b-4617-b586-34f1ce67bb40_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20683/195e2b77-b16b-4617-b586-34f1ce67bb40_figure1.gif"></a><div class=caption><h3>Figure 1. The canonical interactions between Bcl-2 family protein subgroups.</h3><p id=d35936e217>The Bcl-2 family of proteins consists of three groups: anti-apoptotic proteins (for example, Bcl-2, Bcl-XL, Bcl-W and Mcl-1), pore-forming pro-apoptotic proteins (for example, Bax and Bak) and the BH3-only proteins. The BH3-only subgroup shows distinct binding preferences for both anti- and pro-apoptotic Bcl-2 proteins. Some BH3-only proteins, such as Noxa and Bad, bind only specific anti-apoptotic proteins. As such, they do not directly activate Bax and Bak and are termed “sensitizer” BH3-only proteins. Other BH3-only proteins, including Bim, Bid and PUMA, can bind both anti- and pro-apoptotic proteins. These either can activate pro-apoptotic Bax and Bak (and thus are termed “direct activators”) or can be inhibited by binding the anti-apoptotic proteins. The BH3-domain of the BH3-only proteins represents a canonical site of interaction with the other subgroups. BH3-mimetics such as ABT-263, ABT-199 and S63845 have been developed to mimic the interaction of specific BH3-only proteins with anti-apoptotic proteins.</p></div></div><p class="" id=d35936e224>Members of the Bcl-2 family can be characterised by sharing at least one homologous region within their sequence, termed Bcl-2 homology or BH-domains<sup><a href="#ref-10">10</a></sup>. Proteins within the family can be grouped based on both the presence of these BH-domains and their function in apoptosis regulation. Bcl-2, along with Bcl-XL, Mcl-1, Bcl-W and A1, are anti-apoptotic and contain four distinct BH-domains (sometimes referred to as BH1–4 proteins). These anti-apoptotic proteins are responsible for binding pro-apoptotic Bcl-2 proteins to inhibit their function. The pro-apoptotic Bcl-2 proteins can be further categorised on the basis of function and sequence homology. Like the anti-apoptotic members, the effector proteins Bax, Bak and Bok also have multiple BH-domains. Bax and Bak are the best understood. Both promote apoptosis by effecting mitochondrial outer membrane permeabilisation (MOMP), releasing pro-apoptotic factors such as cytochrome <i>c</i> and SMAC/Diablo. Bax and Bak, along with the anti-apoptotic proteins, also have a C-terminal tail anchor region that targets these proteins to membranes, predominately (though not exclusively) to mitochondria. The role of Bok is less understood, and although it does share homology with Bax and Bak, Bok appears to be predominantly regulated through proteasomal degradation at the endoplasmic reticulum<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d35936e238>The final group of Bcl-2 proteins, termed BH3-only proteins because they share only the single region of homology with the other family members, are the most diverse<sup><a href="#ref-12">12</a></sup>. Proteins in this group include Bid, Bad, Bim, Noxa, PUMA, Bmf, Hrk and Bik. These can bind directly to both pro- and anti-apoptotic multidomain proteins via their BH3-domain, which comprises a short amphipathic α-helix. This binding can either inhibit the anti-apoptotic proteins or directly activate pro-apoptotic Bax and Bak. Differences in the sequence of BH3-domains mean that different BH3-only proteins have distinct binding specificities for different multidomain proteins. Bim and Bid are promiscuous, binding most pro- and anti-apoptotic proteins, whereas Bad binds only Bcl-2, Bcl-XL and Bcl-W, and Noxa binds just Mcl-1 and A1.</p><p class="" id=d35936e246>The final component contributing to the complexity of apoptosis comprises the plethora of signals controlling both transcriptional and post-translational regulation of the different Bcl-2 family members. The details of these regulatory mechanisms are reviewed in detail elsewhere<sup><a href="#ref-12">12</a></sup>; however, examples relevant to cancer include the transcriptional activation of PUMA and Noxa by the p53 tumour suppressor<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>, potentially linking these BH3-only proteins to chemotherapies inducing genotoxic stress. Other BH3-only proteins are post-translationally regulated; these include Bad, which undergoes phosphorylation on multiple sites in response to the types of growth factor signalling upregulated by many oncogenic mutations in cancer<sup><a href="#ref-15">15</a></sup>. The key concept is that a cell will be expressing a range of pro- and anti-apoptotic Bcl-2 proteins that together set a threshold above which further cytotoxic damage will result in MOMP.</p><p class="" id=d35936e264>This intricate balance of interactions between the pro- and anti-apoptotic Bcl-2 proteins allows them to act as a buffer against the constantly changing signals reaching the cell, keeping healthy cells alive whilst killing any cells that either become too damaged or are surplus to requirement. As cells acquire or become exposed to damage, the complex Bcl-2 landscape shifts through changes in the expression or function of pro-apoptotic members and downregulation or neutralisation of anti-apoptotic ones (<a href="#f2">Figure 2</a>). These changes make cells more primed to undergo MOMP. Conversely, alterations such as overexpression of anti-apoptotic proteins make cells less primed. Therefore, it is unsurprising that cancer cells show alteration in their Bcl-2 landscape.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20683/195e2b77-b16b-4617-b586-34f1ce67bb40_figure2.gif"><img alt="195e2b77-b16b-4617-b586-34f1ce67bb40_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20683/195e2b77-b16b-4617-b586-34f1ce67bb40_figure2.gif"></a><div class=caption><h3>Figure 2. Apoptotic priming describes the proximity of a cell to the point of commitment to mitochondrial outer membrane permeabilisation (MOMP).</h3><p id=d35936e280>Cells can exist in different states of priming, which essentially describes how close the cell lies to MOMP, which is dependent upon the functional Bcl-2 protein landscape in that cell. Normal cells can shift their state of priming following changes in cellular stress or exposure to pro-apoptotic stimuli, such as DNA damage or growth factor deprivation. These signals result in changes in the degree of priming, although this may not result in MOMP. Normal cells are often insensitive to BH3-mimetics. In contrast, cancer cells are often primed and closer to MOMP. Overexpression of anti-apoptotic Bcl-2 proteins in cancer cells can suppress MOMP by sequestering pro-apoptotic Bcl-2 family members. However, this results in them being extremely sensitive to BH3-mimetics, which can compete with the pro-apoptotic proteins, releasing them from their anti-apoptotic partners to drive MOMP<sup><a href="#ref-37">37</a></sup>.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35936e294>Overexpression of Bcl-2: a paradigm for cancer cells altering the apoptotic landscape</h2><p class="" id=d35936e297>Since the original characterisation of the (14;18) translocation in lymphoma, Bcl-2 protein expression has been found to be elevated in a range of cancers, including chronic lymphocytic leukaemia (CLL)<sup><a href="#ref-16">16</a></sup>, small cell lung carcinoma (SCLC)<sup><a href="#ref-17">17</a></sup> and neuroblastoma<sup><a href="#ref-18">18</a></sup>. However, translocations or mutations within anti-apoptotic Bcl-2 family genes in general are the exception for how these become dysregulated in cancer. More common are gene amplifications or increased protein expression, the latter occurring through increased transcription, translation or protein stability. Of the anti-apoptotic members of the family, <i>BCL2L1</i> (encoding Bcl-XL) and <i>MCL1</i> are the most frequent genes amplified in human cancers<sup><a href="#ref-19">19</a></sup>. The consequences of anti-apoptotic Bcl-2 protein overexpression will be to increase the threshold for the level of damage required to induce MOMP. This functional outcome is seen in the multitude of studies where the expression of these proteins has been artificially manipulated, be it in cells or mice.</p><p class="" id=d35936e323>Although overexpression of anti-apoptotic Bcl-2 proteins is seen in many cancers, by itself this is only weakly oncogenic, if at all. Indeed, the (14;18) translocation involving <i>BCL2</i> has also been seen in healthy lymphocytes<sup><a href="#ref-20">20</a></sup>. When overexpression of anti-apoptotic Bcl-2 proteins has been engineered into mouse models, it has not by itself been profoundly oncogenic, and any predisposition to tumours seen tends to have a long latency<sup><a href="#ref-21">21</a></sup>. Amplification of anti-apoptotic Bcl-2 protein expression, however, does combine potently with other oncogenes, such as Myc, and this is seen in human tumours as well as in animal models and cell lines<sup><a href="#ref-19">19</a>,<a href="#ref-22">22</a>–<a href="#ref-25">25</a></sup>. Mcl-1 can also undergo co-amplification with Myc in breast cancer<sup><a href="#ref-26">26</a></sup>.</p><p class="" id=d35936e351>Does anti-apoptotic Bcl-2 protein overexpression make cancer cells more resistant to apoptosis than healthy cells? The answer appears to be more complex (<a href="#f2">Figure 2</a>). Overexpression of Bcl-2 in tumours can sensitise them to apoptosis when the function of Bcl-2 is inhibited, and in some cancers, high Bcl-2 expression is associated with better prognosis<sup><a href="#ref-27">27</a></sup>. In contrast, however, Mcl-1 is associated with poor prognosis in breast cancer<sup><a href="#ref-28">28</a></sup>. Cancer cells are generally more genetically unstable than normal cells and, as such, are much closer to the threshold for MOMP than healthy counterparts<sup><a href="#ref-29">29</a></sup>. Thus, the increased expression of anti-apoptotic proteins in these cells is required to suppress the pro-apoptotic effect of oncogenic transformation and genomic instability. Cancer cells that are dependent on overexpressed Bcl-2 are thus susceptible to its inhibition. This forms the basis for BH3-mimetics like venetoclax (discussed below).</p><p class="" id=d35936e369>Downregulation of pro-apoptotic Bcl-2 proteins is functionally equivalent to overexpressing the anti-apoptotic ones, and loss of expression of pro-apoptotic proteins is seen in a range of cancers. Loss of the Bim gene is present in renal cell carcinoma<sup><a href="#ref-30">30</a></sup> and in coordination with downregulation of PUMA in samples of patients with Epstein–Barr virus<sup><a href="#ref-31">31</a></sup>. Deletion of PUMA is also found in about 40% of Burkitt lymphoma cases<sup><a href="#ref-32">32</a></sup>, and its downregulation is seen in a range of cancer types (for example, by microRNAs in glioblastoma)<sup><a href="#ref-33">33</a></sup>. The role of PUMA in the p53 response would fit with its downregulation promoting genetic instability and resistance to genotoxic therapies. Changes in the pro-apoptotic proteins that drive MOMP are also seen in cancer. Frameshift mutations in Bax are found in colon cancer<sup><a href="#ref-34">34</a>,<a href="#ref-35">35</a></sup>, and a loss of function due to silencing by miR-365 was seen in cutaneous squamous cell carcinoma<sup><a href="#ref-36">36</a></sup>. However, as with the anti-apoptotic proteins, mouse models where individual pro-apoptotic Bcl-2 family proteins have been deleted have not significantly predisposed those animals to tumours (summarised in <a href="#ref-10">10</a>). Gene deletion studies in mice show that Bax and Bak are largely redundant, and loss of one or the other has no overt oncogenic effect. Bad and Bid knockout mice are predisposed to lymphoma and myeloid tumours respectively, but again with a long latency. As with anti-apoptotic Bcl-2 proteins, loss of pro-apoptotic proteins can cooperate with other oncogenes to accelerate tumour development and progression.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35936e406>Exploiting the apoptotic landscape of cancer for therapy</h2><p class="" id=d35936e409>The implication of altered Bcl-2 protein expression in tumours is that the sensitivity of those tumours to apoptosis in response to a variety of therapies will change. Recent developments allow changes in the Bcl-2 protein landscape of tumours to be exploited. The most promising approaches are based upon BH3-only protein specificity for binding the multidomain anti-apoptotic proteins and the changes in cancer cells that make them reliant on those anti-apoptotic proteins to stay alive<sup><a href="#ref-37">37</a></sup>. This understanding can be used both to test how a tumour’s Bcl-2 landscape determines how it will respond to chemotherapy and to therapeutically manipulate that landscape to sensitise or kill cancer cells.</p><p class="" id=d35936e416>Conventional chemotherapies kill cells via the mitochondrial pathway of apoptosis. Therefore, the myriad of variations in expression and function of pro- and anti-apoptotic Bcl-2 proteins combine in a cancer cell to determine how that cell responds to a drug designed to activate that process. Testing where that apoptotic threshold lies can predict therapeutic response before subjecting a patient to potentiality prolonged, ineffective and harmful treatments. BH3 profiling can measure mitochondrial priming in primary cancer cells isolated directly from patients<sup><a href="#ref-38">38</a></sup>. By exposing mitochondria from these cancer cells to peptides mimicking the functional domains of BH3-only proteins and measuring mitochondrial depolarisation as a surrogate readout for MOMP, it is possible to determine the apoptotic threshold of cells in a relatively rapid test. BH3-profiling therefore can identify cancer cells that are reliant on specific subsets of anti-apoptotic Bcl-2 proteins for survival, based upon the response to BH3-domain peptides with distinct binding specificities for those anti-apoptotic proteins<sup><a href="#ref-39">39</a></sup>. For example, primary samples from patients with acute myeloid leukaemia (AML) are significantly more primed than cells from healthy patients, as treatment with a Bim BH3-peptide causes significant apoptosis in the AML samples<sup><a href="#ref-40">40</a></sup>. AML cells that showed strong mitochondrial depolarisation in response to BH3-peptides came from patients who subsequently presented a better response to therapy than those whose cancer cells were relatively unresponsive. Similar results were found in other cancers, including lymphoma cell lines<sup><a href="#ref-41">41</a></sup>, primary acute lymphoblastic leukaemia (ALL)<sup><a href="#ref-42">42</a></sup> and CLL<sup><a href="#ref-43">43</a></sup>.</p><p class="" id=d35936e444>The potential advantage of BH3-profiling is that the assay is based upon a functional test rather than an expressed biomarker which may not reflect a biological response. As there are a multitude of ways that cancer cells can alter Bcl-2 protein function, testing a limited set of expressed biomarkers may not predict patient response. Functionally testing this threshold does, provided that cancer cells can be isolated directly from the patient while not altering the Bcl-2 landscape. However, BH3-profiling requires cells to be dissociated, and how robustly it will predict responses in cancers where signals from the tumour microenvironment influence apoptotic priming remains to be seen.</p><p class="" id=d35936e447>Perhaps the most significant advance in applying knowledge of apoptotic regulation has been the development of BH3-mimetics. Venetoclax, the first drug in this class to be approved, is now in clinical use for treatment of CLL<sup><a href="#ref-44">44</a></sup>. Our understanding of how the Bcl-2 landscape sets apoptotic priming through the interaction of the different proteins within the family has highlighted points at which these interactions can be targeted. One specific vulnerability is the BH3-domain binding groove of anti-apoptotic Bcl-2 proteins. The initial report of ABT-737 in 2005 established the paradigm for these novel targeted drugs<sup><a href="#ref-45">45</a></sup>. A nuclear magnetic resonance (NMR)-based screen initially identified compounds that interacted Bcl-XL within the same hydrophobic groove within which BH3-only proteins bound, thus with the potential to compete for binding. These compounds were developed into ABT-737, a small molecule that shared the binding profile of the BH3-domain of Bad, with high affinity for Bcl-XL, Bcl-2 and Bcl-W but not with Mcl-1 or A1. As such, ABT-737 could compete with BH3-only proteins for binding to Bcl-XL, Bcl-2 and Bcl-W and thus increase apoptotic priming in cells. ABT-737 showed promise by inducing regression of solid tumours in xenografts of lymphoma and SCLC<sup><a href="#ref-45">45</a></sup> as well as part of a combination therapy for head and neck squamous cell carcinoma<sup><a href="#ref-46">46</a></sup>.</p><p class="" id=d35936e467>The lack of oral bioavailability prevented ABT-737 from being clinically useful but led to the development of ABT-263 (marketed as navitoclax)<sup><a href="#ref-47">47</a></sup>. Navitoclax had essentially the same binding characteristics for anti-apoptotic Bcl-2 proteins as ABT-737 and was successful in inducing regression of SCLC and ALL xenografts in mice<sup><a href="#ref-48">48</a></sup>. However, acute thrombocytopenia was observed in multiple <i>in vivo</i> studies in mice, dogs and rats<sup><a href="#ref-49">49</a></sup> as well as in clinical trials in patients with lymphoid tumours<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. Although most adult tissues are remarkably tolerant of ABT-263, clinical testing identified a previously unknown role for Bcl-XL in platelet lifespan<sup><a href="#ref-52">52</a></sup>. Although initially this was a block on the use of navitoclax in patients, currently there are trials to test its safety by controlling thrombocytopenia through appropriate clinical management and dosing. Additionally, a previous clinical trial examining the effect of the aurora A kinase inhibitor MLN8237 showed a modest effect on solid tumours in combination with ABT-263<sup><a href="#ref-53">53</a></sup>. As <i>BCL2L1</i> is one of the anti-apoptotic genes most often amplified in solid tumours, it will be important to therapeutically target this anti-apoptotic member despite the on-target side effects.</p><p class="" id=d35936e504>If specific tumours are dependent upon Bcl-2, then BH3-mimetics with a single-molecule specificity would be desirable to minimise adverse effects. Modifying ABT-263 to increase its specificity for Bcl-2 resulted in ABT-199<sup><a href="#ref-54">54</a></sup>. ABT-199 was trialled in CLL, where it showed a remarkable effectiveness as a single agent<sup><a href="#ref-55">55</a></sup>. Indeed, ABT-199 was so effective in some cases that it caused potentially fatal tumour lysis syndrome, subsequently controlled by changes in dosing. ABT-199 (marketed as venetoclax) has been approved as a single agent for treatment of CLL patients with a 17p deletion who have had at least one prior therapy<sup><a href="#ref-44">44</a></sup>.</p><p class="" id=d35936e519>Although CLL shows significant dependency on Bcl-2, other cancers are not as sensitive to inhibiting it alone. In November 2018, venetoclax was granted accelerated approval by the US Food and Drug Administration for the treatment of AML in combination with zacitidine, decitabine or low-dose cytarabine in adults who are 75 or older or who have comorbidities that prevent the use of other treatments. There are numerous studies under way examining the use of ABT-199 either alone or in combination in the treatment of multiple other cancer types. The majority of these are still in early stages, but<i></i> phase III trials are examining long-term safety data for the use of venetoclax in treating CLL and AML as well as multiple myeloma and ALL. There is also a phase III trial investigating the effects of venetoclax in combination with ibrutinib to treat mantle cell lymphoma. A more recent study examining the addition of venetoclax for treatment of pancreatic cancer has shown inhibition of growth in xenograft mouse models to be more effective when both drugs are used in combination<sup><a href="#ref-56">56</a></sup>. Venetoclax has also shown promise in combination with histone deacetylase (HDAC) inhibition in treating multiple myeloma<sup><a href="#ref-57">57</a></sup>. Thus, BH3-mimetics will undoubtedly be used not just to target tumours where Bcl-2 dependency is keeping them alive but to shift the apoptotic landscape to make them more primed for MOMP and thus susceptible to other treatments. This concept has been tested with what is termed dynamic BH3-profiling, where response of isolated cancer cells to BH3-peptides was tested in conjunction with other targeted cancer therapies<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d35936e536>However, it is not only Bcl-2 which is aberrantly regulated in cancer. Although CLL is largely Bcl-2–dependent, other cancers use a combination of anti-apoptotic proteins to survive, requiring either multiple BH3-mimetics or ones with broader binding characteristics. As detailed by the National Cancer Institute (<a target=xrefwindow href="https://www.cancer.gov" id=d35936e538>https://www.cancer.gov</a>), navitoclax, alone or in combination with other drugs, is still under investigation for use in a number of malignancies, including relapsed small cell lung cancer and metastatic melanoma. Trials of navitoclax with rutiximab for lymphoid malignancies are ongoing<sup><a href="#ref-58">58</a></sup>. Bcl-XL–specific mimetics have been developed<sup><a href="#ref-59">59</a></sup>, and there is still significant need in targeting this appropriately in Bcl-XL–dependent tumours. Mcl-1 is also a target of interest due to its expression in numerous cancers, such as breast tumours with poor outcomes<sup><a href="#ref-28">28</a></sup>. Although Mcl-1 initially proved a difficult target to develop specific mimetics for a number of years, potent inhibitors have now been developed<sup><a href="#ref-60">60</a>–<a href="#ref-63">63</a></sup>, of which S63845 from Servier shows the greatest specificity over Bcl-2 and Bcl-XL<sup><a href="#ref-64">64</a></sup>. These compounds are undergoing trials. Furthermore, small molecules have been developed that, rather than inhibiting anti-apoptotic Bcl-2 proteins, directly activate pro-apoptotic ones such as Bax<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. Intriguingly, the Bax-activating compound BTSA1 was found to kill AML cells while being tolerated by healthy cells, both <i>in vitro</i> and <i>in vivo</i>. Overall, the area of BH3-mimetics and related drugs is expanding and offers the exciting potential of targeting apoptosis directly in cancer.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35936e582>Acquired resistance to BH3-mimetics: the apoptotic landscape as a moving target</h2><p class="" id=d35936e585>Venetoclax it is not a panacea for cancer therapy. A common problem with many targeted drugs against tumour-specific mutations is acquired resistance, seen with imatinib in patients with chronic myeloid leukaemia (CML)<sup><a href="#ref-67">67</a></sup>, vemurafenib in melanoma<sup><a href="#ref-68">68</a></sup> and cetuximab in colorectal cancer<sup><a href="#ref-69">69</a></sup>. Acquired resistance is often due to <i>de novo</i> mutations in the drug targets that impede the drugs’ mechanism of action. For example, acquired <i>BCR-ABL</i> mutations in patients with CML block imatanib binding to the kinase domain. Similarly, a single amino-acid substitution in the extracellular region of the epidermal growth factor receptor prevents cetuximab from binding in colorectal cancer patients presenting with acquired resistance. Thus, given the highly targeted nature of venetoclax, the emergence of acquired resistance would be expected. Indeed, mechanisms analogous to those seen with other targeted drugs have been identified both experimentally and in clinical trials.</p><p class="" id=d35936e606>Studies specifically tried to anticipate the emergence of resistance to BH3-mimetics using a murine mantel cell lymphoma (MCL) model. MCL lines were exposed to increasing doses of ABT-737 and ABT-199 over several months until resistant cells emerged<sup><a href="#ref-70">70</a></sup>. Drug resistance was seen both <i>in vitro</i> and <i>in vivo</i> and was maintained even when cells were subsequently cultured in the absence of drug and then re-exposed. The resistance was specific to the BH3-mimetics, as the cells readily underwent apoptosis when treated with other anti-cancer drugs. Intriguingly, one human MCL line showed acquired resistance to a wider range of anti-cancer drugs, including taxol and doxorubicin. The study authors found that two distinct mutations had been acquired in the mouse and human cells. In the mouse lines, two novel missense mutations in Bcl-2 itself had emerged, resulting in amino-acid substitutions within the BH3-binding pocket (F101C and F101L). These two substitutions resulted in significantly reduced binding of both ABT-737 and ABT-199 to the variant Bcl-2. In contrast, the resistant human MCL line had acquired a missense mutation in the pro-apoptotic effector Bax, specifically an amino-acid substitution within its mitochondrial targeting sequence leading to a more general reduction in sensitivity to pro-apoptotic drugs.</p><p class="" id=d35936e619>Although trials with CLL patients who had undergone previous drug treatments showed a good response to venetoclax, disease progression occurred in a number of patients after 2 to 3 years on the BH3-mimetic<sup><a href="#ref-44">44</a></sup>. Two independent studies found that this acquired resistance in a number of patients on long-term venetoclax treatment resulted from mutations in the <i>BCL-2</i> gene, in the same region as those identified in experimentally induced resistance in the murine study<sup><a href="#ref-71">71</a>,<a href="#ref-72">72</a></sup>. In one study<sup><a href="#ref-71">71</a></sup>, seven patients with recurrent venetoclax-resistant CLL were found with a glycine-to-valine substitution at position 101 within the BH3-binding pocket. The patients’ tumours did not have this variant prior to venetoclax treatment. The mutations were first detected at a low frequency after many months of drug exposure and preceded disease recurrence by several months. The second study<sup><a href="#ref-72">72</a></sup> found the same G101V substitution in four patients with recurrent CLL, one of which had tumour cells with a second, independent Bcl-2 variant containing a substitution of aspartate 103 to tyrosine, again within the BH3-binding pocket.</p><p class="" id=d35936e644>In both the experimental and clinical occurrences of venetoclax resistance, the Bcl-2 variants identified significantly reduced binding to ABT-737 and ABT-199 but had minimal effect on binding to pro-apoptotic Bcl-2 proteins such as Bax and Bim<sup><a href="#ref-71">71</a>,<a href="#ref-73">73</a></sup>. As such, the specific variants selected for in patients resulted in reduced drug sensitivity whilst maintaining Bcl-2 anti-apoptotic function. Recent structural analysis of the G101V, F104C and F104L variants has indicated that they all reduce ABT-199 binding but through distinct mechanisms<sup><a href="#ref-73">73</a></sup>. This indicates that despite their well-defined mechanism of action, BH3-mimetics do not fully recapitulate the binding of full-length BH3-only proteins to their anti-apoptotic partners. Interestingly, a number of recent <i>in vitro</i> studies have led to similar conclusions. One recent study found that Bim bound to Bcl-XL via two separate interactions, one of which is the classic BH3-groove<sup><a href="#ref-74">74</a></sup>. This dual lock-and-key binding means that Bim is more resistant to competition with ABT-263 than might be expected. In another study, the membrane interaction of Bcl-XL increased its affinity for the BH3-only proteins PUMA and Bim, again resulting in resistance to competition by ABT-263 that was not seen with a soluble version of Bcl-XL<sup><a href="#ref-75">75</a></sup>. Since the isolation of ABT-737 and the clinical adoption of venetoclax, other BH3-mimetics which show binding specificities for distinct Bcl-2 family members, such as S55746, have been generated<sup><a href="#ref-76">76</a></sup>. The potential for distinct binding properties suggests that it is possible overcome the acquired venetoclax resistance that is emerging, and the structural information on venetoclax-resistant Bcl-2 variants will provide a rational basis for drug optimisation<sup><a href="#ref-73">73</a></sup>. However, there are clearly still some aspects of the underlying biology that need to be understood.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d35936e682>Dynamic heterogeneity of apoptosis in healthy tissues and cancer</h2><p class="" id=d35936e685>Apoptotic priming in normal cells and tissues varies dynamically at multiple levels. This variation can be seen between different adult tissues, within the same tissue at distinct developmental stages, between individual cells within a tissue, and in the same cell at different times as that cell is exposed to damage or changes in signalling. The apoptotic landscape is constantly shifting, which presents difficulties when targeting cancer cells whilst minimising the damage to healthy tissue.</p><p class="" id=d35936e688>During embryonic development, where significant levels of apoptosis occur, changes in Bcl-2 protein function are linked to distinct developmental events. In the developing nervous system of mice, neuronal Bcl-2 levels significantly decrease by 5 months of age<sup><a href="#ref-77">77</a></sup>. Bcl-XL and Mcl-1 play key roles in the survival of immature B cells during development, whereas Bcl-2 is required for survival of mature B cells<sup><a href="#ref-78">78</a></sup>. The shifting balance of priming during development is also influenced by changes in pro-apoptotic Bcl-2 proteins, although as discussed above in relation to cancer predisposition, individual BH3-only proteins seem not to have significant roles in the development of most tissues. However, a recent study found that subtle changes in the balance of pro- and anti-apoptotic Bcl-2 proteins have profound effects during craniofacial development<sup><a href="#ref-79">79</a></sup>.</p><p class="" id=d35936e703>Changes in the apoptotic threshold are also apparent post-natally and during development into adults. A recent study used BH3-profiling to compare apoptotic priming in paediatric and adult tissues<sup><a href="#ref-80">80</a></sup>. The results showed that many adult tissues are profoundly insensitive to apoptosis, and mitochondria from these tissues showed low responses to a broad panel of BH3-only protein peptides. In contrast, many of the same embryonic and post-natal tissues were sensitive to mitochondrial apoptosis. During post-natal development, the overall landscape of many Bcl-2 proteins changes, altering the sensitivity of these tissues, with a general reduction in expression of Bax and Bak with age<sup><a href="#ref-80">80</a></sup>. This explains not only why many adult tissues show a broad tolerance to the new BH3-mimetics and many genotoxic drugs but also why children are more at risk of toxic side effects to chemotherapy. Changes in age-related apoptotic priming were linked to c-Myc, which is expressed in developing tissues and has been linked to changes in apoptotic sensitivity. Forced expression of c-Myc in adult mouse brain increased the apoptotic response to genotoxic damage. This response occurred at a single-cell level, and those cells expressing c-Myc showed increased sensitivity to apoptosis. Thus, apoptotic priming can be set at the level of the individual cell, a further level of heterogeneity that impacts on cancer therapy.</p><p class="" id=d35936e714>Many of the signalling pathways that control cell proliferation and Bcl-2 protein function also show single-cell heterogeneity in their activity<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup>. Therefore, it should not be surprising that apoptosis shows significant cell-to-cell variation. Single cells can also shift their apoptotic threshold rapidly in response to changes in internal and external signals<sup><a href="#ref-83">83</a></sup>. One way this can occur is through Bcl-2 proteins continuously shuttling between cytosol and mitochondria, buffering cells against tolerable levels of stress signalling<sup><a href="#ref-83">83</a></sup>. Where the apoptotic threshold of individual cells is dynamic, the cell population reaches an equilibrium between sensitivity and resistance to pro-apoptotic stimuli<sup><a href="#ref-84">84</a></sup>. Subsequently, the outcome following exposure to an apoptotic signal varies significantly within and between cell populations<sup><a href="#ref-85">85</a></sup>. Thus, targeting cancer cells for apoptosis via disrupting Bcl-2 protein interactions is complicated as our current knowledge of these single-cell dynamics is limited. Although predictive tools such as BH3 profiling provide an indication as to treatment outcome at a tissue level, such tests are only a snapshot in time of the population response and may not predict levels of resistance to specific drug combinations.</p><p class="" id=d35936e741>However, this ability of cells to rapidly shift their apoptotic sensitivity has the potential to be exploited through approaches such as dynamic BH3 profiling<sup><a href="#ref-38">38</a></sup>. This allows the effect of targeted drugs, such as kinase inhibitors, on apoptotic threshold of cancer cells to be determined. Many of these drugs target the dynamic signalling pathways that post-translationally alter Bcl-2 protein function through phosphorylation, degradation, or by altering their sub-cellular localisation. With this approach, it may be possible to screen a primary tumour sample for those targeted drugs that increase apoptotic priming. For example, BH3-profiling was able to discriminate CML patients who showed a response to imatinib or not<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d35936e752>Overall, our understanding of how apoptosis is controlled in mammalian cells has reached a level of maturity whereby it can be rationally applied in a clinical setting. However, there are still levels of complexity in understanding how it is dynamically controlled within single cells and populations of those cells. This needs to be explored in more depth in order to maximise how we can manipulate cell death therapeutically.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d35936e759 class=n-a></a><h2 class=main-title id=d35936e761>Acknowledgements</h2><p class="" id=d35936e764>The authors thank Robert Pedley of University of Manchester for preparing the figures and for comments on the manuscript.</p></div><div class=back-section><a name=d35936e768 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d36508>References</h2><div class="section ref-list"><a name=d35936e768 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d35936e775 class=n-a></a>Carswell EA, Old LJ, Kassel RL, <i> et al.</i>: An endotoxin-induced serum factor that causes necrosis of tumors. <i>Proc Natl Acad Sci U S A.</i> 1975; <b>72</b>(9): 3666–70. <a target=xrefwindow id=d35936e786 href="http://www.ncbi.nlm.nih.gov/pubmed/1103152">PubMed Abstract </a> | <a target=xrefwindow id=d35936e789 href="https://doi.org/10.1073/pnas.72.9.3666">Publisher Full Text </a> | <a target=xrefwindow id=d35936e793 href="http://www.ncbi.nlm.nih.gov/pmc/articles/433057">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727350410"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e802 class=n-a></a>Fulda S: Smac Mimetics to Therapeutically Target IAP Proteins in Cancer. <i>Int Rev Cell Mol Biol.</i> 2017; <b>330</b>: 157–169. <a target=xrefwindow id=d35936e810 href="http://www.ncbi.nlm.nih.gov/pubmed/28215531">PubMed Abstract </a> | <a target=xrefwindow id=d35936e813 href="https://doi.org/10.1016/bs.ircmb.2016.09.004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727350410">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727640792"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e826 class=n-a></a>von Karstedt S, Montinaro A, Walczak H: Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. <i>Nat Rev Cancer.</i> 2017; <b>17</b>(6): 352–366. <a target=xrefwindow id=d35936e834 href="http://www.ncbi.nlm.nih.gov/pubmed/28536452 ">PubMed Abstract </a> | <a target=xrefwindow id=d35936e837 href="https://doi.org/10.1038/nrc.2017.28">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727640792">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d35936e850 class=n-a></a>Mullard A: Pioneering apoptosis-targeted cancer drug poised for FDA approval. <i>Nat Rev Drug Discov.</i> 2016; <b>15</b>(3): 147–9. <a target=xrefwindow id=d35936e858 href="http://www.ncbi.nlm.nih.gov/pubmed/26931080">PubMed Abstract </a> | <a target=xrefwindow id=d35936e861 href="https://doi.org/10.1038/nrd.2016.23">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d35936e870 class=n-a></a>Fukuhara S, Rowley JD: Chromosome 14 translocations in non-Burkitt lymphomas. <i>Int J Cancer.</i> 1978; <b>22</b>(1): 14–21. <a target=xrefwindow id=d35936e878 href="http://www.ncbi.nlm.nih.gov/pubmed/355152">PubMed Abstract </a> | <a target=xrefwindow id=d35936e881 href="https://doi.org/10.1002/ijc.2910220105">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d35936e891 class=n-a></a>Bakhshi A, Jensen JP, Goldman P, <i> et al.</i>: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. <i>Cell.</i> 1985; <b>41</b>(3): 899–906. <a target=xrefwindow id=d35936e902 href="http://www.ncbi.nlm.nih.gov/pubmed/3924412">PubMed Abstract </a> | <a target=xrefwindow id=d35936e905 href="https://doi.org/10.1016/S0092-8674(85)80070-2">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d35936e914 class=n-a></a>Tsujimoto Y, Cossman J, Jaffe E, <i> et al.</i>: Involvement of the bcl-2 gene in human follicular lymphoma. <i>Science.</i> 1985; <b>228</b>(4706): 1440–3. <a target=xrefwindow id=d35936e925 href="http://www.ncbi.nlm.nih.gov/pubmed/3874430">PubMed Abstract </a> | <a target=xrefwindow id=d35936e928 href="https://doi.org/10.1126/science.3874430">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d35936e937 class=n-a></a>Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. <i>Nature.</i> 1988; <b>335</b>(6189): 440–2. <a target=xrefwindow id=d35936e945 href="http://www.ncbi.nlm.nih.gov/pubmed/3262202">PubMed Abstract </a> | <a target=xrefwindow id=d35936e948 href="https://doi.org/10.1038/335440a0">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d35936e957 class=n-a></a>Hanahan D, Weinberg RA: The hallmarks of cancer. <i>Cell.</i> 2000; <b>100</b>(1): 57–70. <a target=xrefwindow id=d35936e965 href="http://www.ncbi.nlm.nih.gov/pubmed/10647931">PubMed Abstract </a> | <a target=xrefwindow id=d35936e968 href="https://doi.org/10.1016/S0092-8674(00)81683-9">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d35936e977 class=n-a></a>Youle RJ, Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. <i>Nat Rev Mol Cell Biol.</i> 2008; <b>9</b>(1): 47–59. <a target=xrefwindow id=d35936e985 href="http://www.ncbi.nlm.nih.gov/pubmed/18097445">PubMed Abstract </a> | <a target=xrefwindow id=d35936e988 href="https://doi.org/10.1038/nrm2308">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d35936e997 class=n-a></a>Llambi F, Wang YM, Victor B, <i> et al.</i>: BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. <i>Cell.</i> 2016; <b>165</b>(2): 421–33. <a target=xrefwindow id=d35936e1008 href="http://www.ncbi.nlm.nih.gov/pubmed/26949185">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1011 href="https://doi.org/10.1016/j.cell.2016.02.026">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1015 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5018360">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d35936e1025 class=n-a></a>Happo L, Strasser A, Cory S: BH3-only proteins in apoptosis at a glance. <i>J Cell Sci.</i> 2012; <b>125</b>(Pt 5): 1081–7. <a target=xrefwindow id=d35936e1033 href="http://www.ncbi.nlm.nih.gov/pubmed/22492984">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1036 href="https://doi.org/10.1242/jcs.090514">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1039 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3324577">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d35936e1048 class=n-a></a>Oda E, Ohki R, Murasawa H, <i> et al.</i>: Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. <i>Science.</i> 2000; <b>288</b>(5468): 1053–8. <a target=xrefwindow id=d35936e1059 href="http://www.ncbi.nlm.nih.gov/pubmed/10807576">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1062 href="https://doi.org/10.1126/science.288.5468.1053">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d35936e1071 class=n-a></a>Nakano K, Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. <i>Mol Cell.</i> 2001; <b>7</b>(3): 683–94. <a target=xrefwindow id=d35936e1079 href="http://www.ncbi.nlm.nih.gov/pubmed/11463392">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1082 href="https://doi.org/10.1016/S1097-2765(01)00214-3">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d35936e1091 class=n-a></a>Fang X, Yu S, Eder A, <i> et al.</i>: Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. <i>Oncogene.</i> 1999; <b>18</b>(48): 6635–40. <a target=xrefwindow id=d35936e1102 href="http://www.ncbi.nlm.nih.gov/pubmed/10597268">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1105 href="https://doi.org/10.1038/sj.onc.1203076">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d35936e1114 class=n-a></a>Hanada M, Delia D, Aiello A, <i> et al.</i>: <i>bcl-2</i> gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. <i>Blood.</i> 1993; <b>82</b>(6): 1820–8. <a target=xrefwindow id=d35936e1128 href="http://www.ncbi.nlm.nih.gov/pubmed/8104532">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1132 href="https://doi.org/10.1182/blood.v82.6.1820.1820">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d35936e1141 class=n-a></a>Ikegaki N, Katsumata M, Minna J, <i> et al.</i>: Expression of bcl-2 in small cell lung carcinoma cells. <i>Cancer Res.</i> 1994; <b>54</b>(1): 6–8. <a target=xrefwindow id=d35936e1152 href="http://www.ncbi.nlm.nih.gov/pubmed/8261463">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d35936e1162 class=n-a></a>Castle VP, Heidelberger KP, Bromberg J, <i> et al.</i>: Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. <i>Am J Pathol.</i> 1993; <b>143</b>(6): 1543–50. <a target=xrefwindow id=d35936e1173 href="http://www.ncbi.nlm.nih.gov/pubmed/8256847">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1887263">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2381956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1185 class=n-a></a>Beroukhim R, Mermel CH, Porter D, <i> et al.</i>: The landscape of somatic copy-number alteration across human cancers. <i>Nature.</i> 2010; <b>463</b>(7283): 899–905. <a target=xrefwindow id=d35936e1196 href="http://www.ncbi.nlm.nih.gov/pubmed/20164920">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1199 href="https://doi.org/10.1038/nature08822">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1203 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2826709">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2381956">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d35936e1216 class=n-a></a>Liu Y, Hernandez AM, Shibata D, <i> et al.</i>: BCL2 translocation frequency rises with age in humans. <i>Proc Natl Acad Sci U S A.</i> 1994; <b>91</b>(19): 8910–4. <a target=xrefwindow id=d35936e1227 href="http://www.ncbi.nlm.nih.gov/pubmed/8090743">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1230 href="https://doi.org/10.1073/pnas.91.19.8910">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1234 href="http://www.ncbi.nlm.nih.gov/pmc/articles/44716">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d35936e1243 class=n-a></a>Strasser A, Harris AW, Cory S: E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. <i>Oncogene.</i> 1993; <b>8</b>(1): 1–9. <a target=xrefwindow id=d35936e1251 href="http://www.ncbi.nlm.nih.gov/pubmed/8423986">PubMed Abstract </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d35936e1260 class=n-a></a>Strasser A, Harris AW, Bath ML, <i> et al.</i>: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between <i>myc</i> and <i>bcl</i>-2. <i>Nature.</i> 1990; <b>348</b>(6299): 331–3. <a target=xrefwindow id=d35936e1278 href="http://www.ncbi.nlm.nih.gov/pubmed/2250704">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1281 href="https://doi.org/10.1038/348331a0">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d35936e1290 class=n-a></a>Bissonnette RP, Echeverri F, Mahboubi A, <i> et al.</i>: Apoptotic cell death induced by c-<i>myc</i> is inhibited by <i>bcl</i>-2. <i>Nature.</i> 1992; <b>359</b>(6395): 552–4. <a target=xrefwindow id=d35936e1308 href="http://www.ncbi.nlm.nih.gov/pubmed/1406975">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1311 href="https://doi.org/10.1038/359552a0">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d35936e1321 class=n-a></a>Fanidi A, Harrington EA, Evan GI: Cooperative interaction between c-myc and bcl-2 proto-oncogenes. <i>Nature.</i> 1992; <b>359</b>(6395): 554–6. <a target=xrefwindow id=d35936e1329 href="http://www.ncbi.nlm.nih.gov/pubmed/1406976">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1332 href="https://doi.org/10.1038/359554a0">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d35936e1341 class=n-a></a>Swanson PJ, Kuslak SL, Fang W, <i> et al.</i>: Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-x<sub>L</sub> and c-<i>myc</i>. <i>J Immunol.</i> 2004; <b>172</b>(11): 6684–91. <a target=xrefwindow id=d35936e1359 href="http://www.ncbi.nlm.nih.gov/pubmed/15153484">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1362 href="https://doi.org/10.4049/jimmunol.172.11.6684">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d35936e1371 class=n-a></a>Balko JM, Giltnane JM, Wang K, <i> et al.</i>: Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. <i>Cancer Discov.</i> 2014; <b>4</b>(2): 232–45. <a target=xrefwindow id=d35936e1382 href="http://www.ncbi.nlm.nih.gov/pubmed/24356096">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1385 href="https://doi.org/10.1158/2159-8290.CD-13-0286">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1389 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3946308">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d35936e1398 class=n-a></a>Dawson SJ, Makretsov N, Blows FM, <i> et al.</i>: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. <i>Br J Cancer.</i> 2010; <b>103</b>(5): 668–75. <a target=xrefwindow id=d35936e1409 href="http://www.ncbi.nlm.nih.gov/pubmed/20664598">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1412 href="https://doi.org/10.1038/sj.bjc.6605736">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1416 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2938244">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732499890"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1425 class=n-a></a>Campbell KJ, Dhayade S, Ferrari N, <i> et al.</i>: MCL-1 is a prognostic indicator and drug target in breast cancer. <i>Cell Death Dis.</i> 2018; <b>9</b>(2): 19. <a target=xrefwindow id=d35936e1436 href="http://www.ncbi.nlm.nih.gov/pubmed/29339815">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1439 href="https://doi.org/10.1038/s41419-017-0035-2">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1443 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5833338">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732499890">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d35936e1456 class=n-a></a>Chonghaile TN, Sarosiek KA, Vo TT, <i> et al.</i>: Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. <i>Science.</i> 2011; <b>334</b>(6059): 1129–33. <a target=xrefwindow id=d35936e1467 href="http://www.ncbi.nlm.nih.gov/pubmed/22033517">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1470 href="https://doi.org/10.1126/science.1206727">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1474 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3280949">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d35936e1484 class=n-a></a>Zantl N, Weirich G, Zall H, <i> et al.</i>: Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. <i>Oncogene.</i> 2007; <b>26</b>(49): 7038–48. <a target=xrefwindow id=d35936e1495 href="http://www.ncbi.nlm.nih.gov/pubmed/17486061">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1498 href="https://doi.org/10.1038/sj.onc.1210510">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731430964"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1507 class=n-a></a>Fitzsimmons L, Boyce AJ, Wei W, <i> et al.</i>: Coordinated repression of BIM and PUMA by Epstein-Barr virus latent genes maintains the survival of Burkitt lymphoma cells. <i>Cell Death Differ.</i> 2018; <b>25</b>(2): 241–254. <a target=xrefwindow id=d35936e1518 href="http://www.ncbi.nlm.nih.gov/pubmed/28960205">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1521 href="https://doi.org/10.1038/cdd.2017.150">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5762840">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731430964">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d35936e1538 class=n-a></a>Garrison SP, Jeffers JR, Yang C, <i> et al.</i>: Selection against <i>PUMA</i> gene expression in Myc-driven B-cell lymphomagenesis. <i>Mol Cell Biol.</i> 2008; <b>28</b>(17): 5391–402. <a target=xrefwindow id=d35936e1552 href="http://www.ncbi.nlm.nih.gov/pubmed/18573879">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1556 href="https://doi.org/10.1128/MCB.00907-07">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1559 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2519737">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d35936e1568 class=n-a></a>Zhang CZ, Zhang JX, Zhang AL, <i> et al.</i>: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. <i>Mol Cancer.</i> 2010; <b>9</b>: 229. <a target=xrefwindow id=d35936e1579 href="http://www.ncbi.nlm.nih.gov/pubmed/20813046">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1582 href="https://doi.org/10.1186/1476-4598-9-229">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1586 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2939570">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d35936e1595 class=n-a></a>Rampino N, Yamamoto H, Ionov Y, <i> et al.</i>: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. <i>Science.</i> 1997; <b>275</b>(5302): 967–9. <a target=xrefwindow id=d35936e1606 href="http://www.ncbi.nlm.nih.gov/pubmed/9020077">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1609 href="https://doi.org/10.1126/science.275.5302.967">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d35936e1618 class=n-a></a>Miquel C, Borrini F, Grandjouan S, <i> et al.</i>: Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. <i>Am J Clin Pathol.</i> 2005; <b>123</b>(4): 562–70. <a target=xrefwindow id=d35936e1629 href="http://www.ncbi.nlm.nih.gov/pubmed/15743744">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1632 href="https://doi.org/10.1309/JQ2X-3RV3-L8F9-TGYW">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727670775"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1642 class=n-a></a>Zhou L, Gao R, Wang Y, <i> et al.</i>: Loss of BAX by miR-365 Promotes Cutaneous Squamous Cell Carcinoma Progression by Suppressing Apoptosis. <i>Int J Mol Sci.</i> 2017; <b>18</b>(6): pii: E1157. <a target=xrefwindow id=d35936e1653 href="http://www.ncbi.nlm.nih.gov/pubmed/28556798">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1656 href="https://doi.org/10.3390/ijms18061157">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1660 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5485981">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727670775">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d35936e1673 class=n-a></a>Certo M, Del Gaizo Moore V, Nishino M, <i> et al.</i>: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. <i>Cancer Cell.</i> 2006; <b>9</b>(5): 351–365. <a target=xrefwindow id=d35936e1684 href="http://www.ncbi.nlm.nih.gov/pubmed/16697956">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1687 href="https://doi.org/10.1016/j.ccr.2006.03.027">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725369660"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1696 class=n-a></a>Montero J, Sarosiek KA, DeAngelo JD, <i> et al.</i>: Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. <i>Cell.</i> 2015; <b>160</b>(5): 977–989. <a target=xrefwindow id=d35936e1707 href="http://www.ncbi.nlm.nih.gov/pubmed/25723171">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1710 href="https://doi.org/10.1016/j.cell.2015.01.042">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4391197">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725369660">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726205394"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1727 class=n-a></a>Butterworth M, Pettitt A, Varadarajan S, <i> et al.</i>: BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. <i>Br J Cancer.</i> 2016; <b>114</b>(6): 638–41. <a target=xrefwindow id=d35936e1738 href="http://www.ncbi.nlm.nih.gov/pubmed/26954718">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1741 href="https://doi.org/10.1038/bjc.2016.49">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1745 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4800304">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726205394">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717967902"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1758 class=n-a></a>Vo TT, Ryan J, Carrasco R, <i> et al.</i>: Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. <i>Cell.</i> 2012; <b>151</b>(2): 344–55. <a target=xrefwindow id=d35936e1769 href="http://www.ncbi.nlm.nih.gov/pubmed/23063124">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1772 href="https://doi.org/10.1016/j.cell.2012.08.038">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1776 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3534747">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717967902">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d35936e1789 class=n-a></a>Deng J, Carlson N, Takeyama K, <i> et al.</i>: BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. <i>Cancer Cell.</i> 2007; <b>12</b>(2): 171–85. <a target=xrefwindow id=d35936e1800 href="http://www.ncbi.nlm.nih.gov/pubmed/17692808">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1803 href="https://doi.org/10.1016/j.ccr.2007.07.001">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d35936e1813 class=n-a></a>Del Gaizo Moore V, Schlis KD, Sallan SE, <i> et al.</i>: BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. <i>Blood.</i> 2008; <b>111</b>(4): 2300–9. <a target=xrefwindow id=d35936e1824 href="http://www.ncbi.nlm.nih.gov/pubmed/18056841">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1827 href="https://doi.org/10.1182/blood-2007-06-098012">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1831 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2234061">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1066064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1840 class=n-a></a>Del Gaizo Moore V, Brown JR, Certo M, <i> et al.</i>: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. <i>J Clin Invest.</i> 2007; <b>117</b>(1): 112–21. <a target=xrefwindow id=d35936e1851 href="http://www.ncbi.nlm.nih.gov/pubmed/17200714">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1854 href="https://doi.org/10.1172/JCI28281">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1858 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1716201">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1066064">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733152790"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1871 class=n-a></a>Stilgenbauer S, Eichhorst B, Schetelig J, <i> et al.</i>: Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>JCO.</i> 2018; <b>36</b>(19): 1973–1980. <a target=xrefwindow id=d35936e1882 href="http://www.ncbi.nlm.nih.gov/pubmed/29715056">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1885 href="https://doi.org/10.1200/JCO.2017.76.6840">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733152790">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1026512"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1898 class=n-a></a>Oltersdorf T, Elmore SW, Shoemaker AR, <i> et al.</i>: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. <i>Nature.</i> 2005; <b>435</b>(7042): 677–81. <a target=xrefwindow id=d35936e1909 href="http://www.ncbi.nlm.nih.gov/pubmed/15902208">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1912 href="https://doi.org/10.1038/nature03579">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1026512">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726191420"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e1925 class=n-a></a>Gilormini M, Malesys C, Armandy E, <i> et al.</i>: Preferential targeting of cancer stem cells in the radiosensitizing effect of ABT-737 on HNSCC. <i>Oncotarget.</i> 2016; <b>7</b>(13): 16731–44. <a target=xrefwindow id=d35936e1936 href="http://www.ncbi.nlm.nih.gov/pubmed/26934442">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1939 href="https://doi.org/10.18632/oncotarget.7744">Publisher Full Text </a> | <a target=xrefwindow id=d35936e1943 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4941347">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726191420">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d35936e1956 class=n-a></a>Park CM, Bruncko M, Adickes J, <i> et al.</i>: Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. <i>J Med Chem.</i> 2008; <b>51</b>(21): 6902–15. <a target=xrefwindow id=d35936e1967 href="http://www.ncbi.nlm.nih.gov/pubmed/18841882">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1970 href="https://doi.org/10.1021/jm800669s">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d35936e1980 class=n-a></a>Tse C, Shoemaker AR, Adickes J, <i> et al.</i>: ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. <i>Cancer Res.</i> 2008; <b>68</b>(9): 3421–8. <a target=xrefwindow id=d35936e1991 href="http://www.ncbi.nlm.nih.gov/pubmed/18451170">PubMed Abstract </a> | <a target=xrefwindow id=d35936e1994 href="https://doi.org/10.1158/0008-5472.CAN-07-5836">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d35936e2003 class=n-a></a>Shoemaker AR, Mitten MJ, Adickes J, <i> et al.</i>: The Bcl-2 Family Inhibitor ABT-263 Shows Significant but Reversible Thrombocytopenia in Mice. <i>Blood.</i> 2006; <b>108</b>(11): 1107. <a target=xrefwindow id=d35936e2014 href="https://doi.org/10.1182/blood.V108.11.1107.1107">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d35936e2023 class=n-a></a>Wilson WH, O'Connor OA, Czuczman MS, <i> et al.</i>: Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. <i>Lancet Oncol.</i> 2010; <b>11</b>(12): 1149–59. <a target=xrefwindow id=d35936e2034 href="http://www.ncbi.nlm.nih.gov/pubmed/21094089">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2037 href="https://doi.org/10.1016/S1470-2045(10)70261-8">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3025495">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d35936e2050 class=n-a></a>Kaefer A, Yang J, Noertersheuser P, <i> et al.</i>: Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. <i>Cancer Chemother Pharmacol.</i> 2014; <b>74</b>(3): 593–602. <a target=xrefwindow id=d35936e2061 href="http://www.ncbi.nlm.nih.gov/pubmed/25053389">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2064 href="https://doi.org/10.1007/s00280-014-2530-9">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1071045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2073 class=n-a></a>Mason KD, Carpinelli MR, Fletcher JI, <i> et al.</i>: Programmed anuclear cell death delimits platelet life span. <i>Cell.</i> 2007; <b>128</b>(6): 1173–86. <a target=xrefwindow id=d35936e2084 href="http://www.ncbi.nlm.nih.gov/pubmed/17382885">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2087 href="https://doi.org/10.1016/j.cell.2007.01.037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1071045">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d35936e2100 class=n-a></a>Cervantes A, Elez E, Roda D, <i> et al.</i>: Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clin Cancer Res.</i> 2012; <b>18</b>(17): 4764–74. <a target=xrefwindow id=d35936e2111 href="http://www.ncbi.nlm.nih.gov/pubmed/22753585">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2114 href="https://doi.org/10.1158/1078-0432.CCR-12-0571">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717973247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2124 class=n-a></a>Souers AJ, Leverson JD, Boghaert ER, <i> et al.</i>: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nat Med.</i> 2013; <b>19</b>(2): 202–8. <a target=xrefwindow id=d35936e2135 href="http://www.ncbi.nlm.nih.gov/pubmed/23291630">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2138 href="https://doi.org/10.1038/nm.3048">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717973247">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725994198"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2151 class=n-a></a>Roberts AW, Davids MS, Pagel JM, <i> et al.</i>: Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2016; <b>374</b>(4): 311–22. <a target=xrefwindow id=d35936e2162 href="http://www.ncbi.nlm.nih.gov/pubmed/26639348">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2165 href="https://doi.org/10.1056/NEJMoa1513257">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725994198">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735321996"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2178 class=n-a></a>Duan Z, Chinn D, Tu MJ, <i> et al.</i>: Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. <i>Transl Oncol.</i> 2019; <b>12</b>(4): 683–692. <a target=xrefwindow id=d35936e2189 href="http://www.ncbi.nlm.nih.gov/pubmed/30844579">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2192 href="https://doi.org/10.1016/j.tranon.2019.01.009">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2196 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6402293">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735321996">F1000 Recommendation</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735287837"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2209 class=n-a></a>Ramakrishnan VG, Miller KC, Macon EP, <i> et al.</i>: Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. <i>Haematologica.</i> 2019; <b>104</b>(10): 2061–2074. <a target=xrefwindow id=d35936e2220 href="http://www.ncbi.nlm.nih.gov/pubmed/30846494">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2223 href="https://doi.org/10.3324/haematol.2018.211110">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735287837">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725400916"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2236 class=n-a></a>Kipps TJ, Eradat H, Grosicki S, <i> et al.</i>: A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. <i>Leuk Lymphoma.</i> 2015; <b>56</b>(10): 2826–33. <a target=xrefwindow id=d35936e2247 href="http://www.ncbi.nlm.nih.gov/pubmed/25797560">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2250 href="https://doi.org/10.3109/10428194.2015.1030638">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4643417">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725400916">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d35936e2267 class=n-a></a>Lessene G, Czabotar PE, Sleebs BE, <i> et al.</i>: Structure-guided design of a selective BCL-X<sub>L</sub> inhibitor. <i>Nat Chem Biol.</i> 2013; <b>9</b>(6): 390–7. <a target=xrefwindow id=d35936e2281 href="http://www.ncbi.nlm.nih.gov/pubmed/23603658">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2285 href="https://doi.org/10.1038/nchembio.1246">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d35936e2295 class=n-a></a>Pelz NF, Bian Z, Zhao B, <i> et al.</i>: Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods. <i>J Med Chem.</i> 2016; <b>59</b>(5): 2054–66. <a target=xrefwindow id=d35936e2306 href="http://www.ncbi.nlm.nih.gov/pubmed/26878343">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2309 href="https://doi.org/10.1021/acs.jmedchem.5b01660">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2313 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5565212">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734655745"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2322 class=n-a></a>Tron AE, Belmonte MA, Adam A, <i> et al.</i>: Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. <i>Nat Commun.</i> 2018: <b>9</b>(1): 5341. <a target=xrefwindow id=d35936e2333 href="http://www.ncbi.nlm.nih.gov/pubmed/30559424">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2336 href="https://doi.org/10.1038/s41467-018-07551-w">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2340 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6297231">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734655745">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725314829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2353 class=n-a></a>Leverson JD, Zhang H, Chen J, <i> et al.</i>: Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). <i>Cell Death Dis.</i> 2015: <b>6</b>(1): e1590. <a target=xrefwindow id=d35936e2364 href="http://www.ncbi.nlm.nih.gov/pubmed/25590800">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2367 href="https://doi.org/10.1038/cddis.2014.561">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2371 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4669759">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725314829">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734083611"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2384 class=n-a></a>Caenepeel S, Brown SP, Belmontes B, <i> et al.</i>: AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. <i>Cancer Discov.</i> 2018: <b>8</b>(12): 1582–1597. <a target=xrefwindow id=d35936e2395 href="http://www.ncbi.nlm.nih.gov/pubmed/30254093">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2398 href="https://doi.org/10.1158/2159-8290.CD-18-0387">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734083611">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726861250"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2411 class=n-a></a>Kotschy A, Szlavik Z, Murray J, <i> et al.</i>: The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature.</i> 2016: <b>538</b>(7626): 477–482. <a target=xrefwindow id=d35936e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/27760111">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2425 href="https://doi.org/10.1038/nature19830">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726861250">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717747970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2438 class=n-a></a>Gavathiotis E, Reyna DE, Bellairs JA, <i> et al.</i>: Direct and selective small-molecule activation of proapoptotic BAX. <i>Nat Chem Biol.</i> 2012: <b>8</b>(7): 639–45. <a target=xrefwindow id=d35936e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/22634637">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2452 href="https://doi.org/10.1038/nchembio.995">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3617124">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717747970">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731931891"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2470 class=n-a></a>Reyna DE, Garner TP, Lopez A, <i> et al.</i>: Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. <i>Cancer Cell.</i> 2017: <b>32</b>(4): 490–505.e10. <a target=xrefwindow id=d35936e2481 href="http://www.ncbi.nlm.nih.gov/pubmed/29017059">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2484 href="https://doi.org/10.1016/j.ccell.2017.09.001">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2488 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5793879">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731931891">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d35936e2501 class=n-a></a>Shah NP, Nicoll JM, Nagar B, <i> et al.</i>: Multiple <i>BCR-ABL</i> kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. <i>Cancer Cell.</i> 2002: <b>2</b>(2): 117–25. <a target=xrefwindow id=d35936e2515 href="http://www.ncbi.nlm.nih.gov/pubmed/12204532">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2519 href="https://doi.org/10.1016/S1535-6108(02)00096-X">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13380974"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2528 class=n-a></a>Poulikakos PI, Persaud Y, Janakiraman M, <i> et al.</i>: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). <i>Nature.</i> 2011: <b>480</b>(7377): 387–90. <a target=xrefwindow id=d35936e2539 href="http://www.ncbi.nlm.nih.gov/pubmed/22113612">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2542 href="https://doi.org/10.1038/nature10662">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3266695">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13380974">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13525956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2559 class=n-a></a>Montagut C, Dalmases A, Bellosillo B, <i> et al.</i>: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. <i>Nat Med.</i> 2012: <b>18</b>(2): 221–3. <a target=xrefwindow id=d35936e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/22270724">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2573 href="https://doi.org/10.1038/nm.2609">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13525956">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d35936e2586 class=n-a></a>Fresquet V, Rieger M, Carolis C, <i> et al.</i>: Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. <i>Blood.</i> 2014: <b>123</b>(26): 4111–9. <a target=xrefwindow id=d35936e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/24786774">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2600 href="https://doi.org/10.1182/blood-2014-03-560284">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734570586"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2609 class=n-a></a>Blombery P, Anderson MA, Gong JN, <i> et al.</i>: Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discov.</i> 2019: <b>9</b>(3): 342–353. <a target=xrefwindow id=d35936e2620 href="http://www.ncbi.nlm.nih.gov/pubmed/30514704">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2623 href="https://doi.org/10.1158/2159-8290.CD-18-1119">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734570586">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735587400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2637 class=n-a></a>Tausch E, Close W, Dolnik A, <i> et al.</i>: Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia. <i>Haematologica.</i> 2019: <b>104</b>(9): e434–e437. <a target=xrefwindow id=d35936e2651 href="http://www.ncbi.nlm.nih.gov/pubmed/31004028">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2655 href="https://doi.org/10.3324/haematol.2019.222588">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6717583">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735587400">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735893617"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2671 class=n-a></a>Birkinshaw RW, Gong JN, Luo CS, <i> et al.</i>: Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. <i>Nat Commun.</i> 2019: <b>10</b>(1): 2385. <a target=xrefwindow id=d35936e2682 href="http://www.ncbi.nlm.nih.gov/pubmed/31160589">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2685 href="https://doi.org/10.1038/s41467-019-10363-1">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2689 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6547681">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735893617">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735304230"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2702 class=n-a></a>Liu Q, Osterlund EJ, Chi X, <i> et al.</i>: Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. <i>eLife.</i> 2019; <b>8</b>: pii: e37689. <a target=xrefwindow id=d35936e2713 href="http://www.ncbi.nlm.nih.gov/pubmed/30860026">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2716 href="https://doi.org/10.7554/eLife.37689">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6414199">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735304230">F1000 Recommendation</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d35936e2733 class=n-a></a>Pécot J, Maillet L, Le Pen J, <i> et al.</i>: Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance. <i>Cell Rep.</i> 2016: <b>17</b>(12): 3347–3358. <a target=xrefwindow id=d35936e2744 href="http://www.ncbi.nlm.nih.gov/pubmed/28009301">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2747 href="https://doi.org/10.1016/j.celrep.2016.11.064">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733195460"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2756 class=n-a></a>Casara P, Davidson J, Claperon A, <i> et al.</i>: S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. <i>Oncotarget.</i> 2018; <b>9</b>(28): 20075–20088. <a target=xrefwindow id=d35936e2767 href="http://www.ncbi.nlm.nih.gov/pubmed/29732004">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2770 href="https://doi.org/10.18632/oncotarget.24744">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2774 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5929447">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733195460">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d35936e2787 class=n-a></a>Merry DE, Veis DJ, Hickey WF, <i> et al.</i>: bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS. <i>Development.</i> 1994: <b>120</b>(2): 301–11. <a target=xrefwindow id=d35936e2798 href="http://www.ncbi.nlm.nih.gov/pubmed/8149910">PubMed Abstract </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d35936e2808 class=n-a></a>Vikström IB, Slomp A, Carrington EM, <i> et al.</i>: MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. <i>Cell Death Dis.</i> 2016; <b>7</b>(8): e2345. <a target=xrefwindow id=d35936e2819 href="http://www.ncbi.nlm.nih.gov/pubmed/27560714">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2822 href="https://doi.org/10.1038/cddis.2016.237">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2826 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5108322">Free Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/734048628"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2835 class=n-a></a>Grabow S, Kueh AJ, Ke F, <i> et al.</i>: Subtle Changes in the Levels of BCL-2 Proteins Cause Severe Craniofacial Abnormalities. <i>Cell Rep.</i> 2018: <b>24</b>(12): 3285–3295.e4. <a target=xrefwindow id=d35936e2846 href="http://www.ncbi.nlm.nih.gov/pubmed/30232009">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2849 href="https://doi.org/10.1016/j.celrep.2018.08.048">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/734048628">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727145932"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2862 class=n-a></a>Sarosiek KA, Fraser C, Muthalagu N, <i> et al.</i>: Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics. <i>Cancer Cell.</i> 2017: <b>31</b>(1): 142–156. <a target=xrefwindow id=d35936e2873 href="http://www.ncbi.nlm.nih.gov/pubmed/28017613">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2876 href="https://doi.org/10.1016/j.ccell.2016.11.011">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2880 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5363285">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727145932">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717982097"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2893 class=n-a></a>Albeck JG, Mills GB, Brugge JS: Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. <i>Mol Cell.</i> 2013: <b>49</b>(2): 249–61. <a target=xrefwindow id=d35936e2901 href="http://www.ncbi.nlm.nih.gov/pubmed/23219535">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2904 href="https://doi.org/10.1016/j.molcel.2012.11.002">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2907 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4151532">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717982097">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d35936e2920 class=n-a></a>Ankers JM, Awais R, Jones NA, <i> et al.</i>: Dynamic NF-κB and E2F interactions control the priority and timing of inflammatory signalling and cell proliferation. <i>eLife.</i> 2016; <b>5</b>: pii: e10473. <a target=xrefwindow id=d35936e2931 href="http://www.ncbi.nlm.nih.gov/pubmed/27185527">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2934 href="https://doi.org/10.7554/eLife.10473">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4869934">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717988358"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e2947 class=n-a></a>Schellenberg B, Wang P, Keeble JA, <i> et al.</i>: Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. <i>Mol Cell.</i> 2013: <b>49</b>(5): 959–71. <a target=xrefwindow id=d35936e2958 href="http://www.ncbi.nlm.nih.gov/pubmed/23375500">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2961 href="https://doi.org/10.1016/j.molcel.2012.12.022">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3594749">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717988358">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d35936e2979 class=n-a></a>Flusberg DA, Roux J, Spencer SL, <i> et al.</i>: Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. <i>Mol Biol Cell.</i> 2013: <b>24</b>(14): 2186–200. <a target=xrefwindow id=d35936e2990 href="http://www.ncbi.nlm.nih.gov/pubmed/23699397">PubMed Abstract </a> | <a target=xrefwindow id=d35936e2993 href="https://doi.org/10.1091/mbc.e12-10-0737">Publisher Full Text </a> | <a target=xrefwindow id=d35936e2997 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3708725">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1116909"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d35936e3006 class=n-a></a>Gascoigne KE, Taylor SS: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. <i>Cancer Cell.</i> 2008: <b>14</b>(2): 111–22. <a target=xrefwindow id=d35936e3014 href="http://www.ncbi.nlm.nih.gov/pubmed/18656424">PubMed Abstract </a> | <a target=xrefwindow id=d35936e3017 href="https://doi.org/10.1016/j.ccr.2008.07.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1116909">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 24 Oct 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1793/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1793/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Wellcome Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK<br/> <p> <div class=margin-bottom> Andrew Gilmore <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Louise King <br/> <span>Roles: </span> Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1793/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 24 Oct 2019, 8:1793 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18872.1">https://doi.org/10.12688/f1000research.18872.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Gilmore A and King L. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20683 data-id=18872 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18872.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1793/v1/pdf?article_uuid=5c0427d5-4cff-45c4-863d-eec794ea9ffa" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18872.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gilmore A and King L. Emerging approaches to target mitochondrial apoptosis in cancer cells [version 1; peer review: 3 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1793 (<a href="https://doi.org/10.12688/f1000research.18872.1" target=_blank>https://doi.org/10.12688/f1000research.18872.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18872 id=mobile-track-article-signin-18872 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18872?target=/articles/8-1793/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20683 /> <input name=articleId type=hidden value=18872 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Peter Czabotar</strong>, Walter and Elizabeth Hall Institute of Medical Research, Australia </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stephen Tait</strong>, Institute of Cancer Sciences, University of Glasgow, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Natasha Kyprianou</strong>, Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 24 Oct 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1793/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1793/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=58777-55684></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=58778-55685></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=58779-55686></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1793/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>24 Oct 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Peter Czabotar</strong>, Walter and Elizabeth Hall Institute of Medical Research, Australia </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stephen Tait</strong>, Institute of Cancer Sciences, University of Glasgow, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Natasha Kyprianou</strong>, Department of Urology and Oncological Sciences, Icahn School of Medicine at Mount Sinai, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1793/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1793/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Emerging approaches to target mitochondrial...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1793/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1793/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1793/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gilmore A and King L');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1793/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1793",
            templates : {
                twitter : "Emerging approaches to target mitochondrial apoptosis in cancer.... Gilmore A and King L, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1793/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Emerging approaches to target mitochondrial apoptosis in cancer cells", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Emerging approaches to target mitochondrial apoptosis in cancer cells", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18872/20683")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20683");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "55684": 0,
                           "55685": 0,
                           "55686": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "e3c6a905-226c-4cf9-9396-fd8ef8674334";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1793.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1793.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1793.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1793.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1793.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>